Autopsy report · NCT05367401

A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“waiting for update from Study Lead”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 1, Phase 2
Sponsor: Novartis Pharmaceuticals
Sponsor type: Industry
Conditions: Myelodysplastic Syndromes; Acute Myeloid Leukemia
Interventions: Sabatolimab; Magrolimab; Azacitidine
Participants: 0

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.